Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guohua Yu

Showing results (201-210 of 237) with videos related to

Pageof 24
Sort By:
Journal of the National Cancer Center|July 22, 2024
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancerHuizi Lei, Yun Ling, Pei Yuan, et al.
British Journal of Cancer|June 21, 2024
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trialWenjia Zuo, Zhonghua Wang, Jun Qian, et al.
BMC Infectious Diseases|September 13, 2020
Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patientsXiudi Han, Xuedong Liu, Liang Chen, et al.
Chinese Medical Journal|December 19, 2023
Impact of inhaled corticosteroid use on elderly chronic pulmonary disease patients with community acquired pneumoniaXiudi Han, Hong Wang, Liang Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|January 15, 2024
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)Ying Cheng, Lin Wu, Dingzhi Huang, et al.
BMC Infectious Diseases|April 28, 2018
Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumoniaXiudi Han, Fei Zhou, Hui Li, et al.
BMJ Open|February 17, 2018
Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre surveyLiang Chen, Fei Zhou, Hui Li, et al.
JAMA Oncology|March 19, 2026
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical TrialJiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Nature Communications|April 9, 2025
Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysisJiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)Hongyun Zhao, Wenxiu Yao, Xuhong Min, et al.
Pageof 24

Showing results (201-210 of 237) with videos related to

Sort By:
Pageof 24
Journal of the National Cancer Center|July 22, 2024
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancerHuizi Lei, Yun Ling, Pei Yuan, et al.
British Journal of Cancer|June 21, 2024
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trialWenjia Zuo, Zhonghua Wang, Jun Qian, et al.
BMC Infectious Diseases|September 13, 2020
Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patientsXiudi Han, Xuedong Liu, Liang Chen, et al.
Chinese Medical Journal|December 19, 2023
Impact of inhaled corticosteroid use on elderly chronic pulmonary disease patients with community acquired pneumoniaXiudi Han, Hong Wang, Liang Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|January 15, 2024
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)Ying Cheng, Lin Wu, Dingzhi Huang, et al.
BMC Infectious Diseases|April 28, 2018
Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumoniaXiudi Han, Fei Zhou, Hui Li, et al.
BMJ Open|February 17, 2018
Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre surveyLiang Chen, Fei Zhou, Hui Li, et al.
JAMA Oncology|March 19, 2026
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical TrialJiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Nature Communications|April 9, 2025
Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysisJiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)Hongyun Zhao, Wenxiu Yao, Xuhong Min, et al.
Pageof 24